References of "Mobasheri, Ali"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA)
Bay-Jensen, Anne-Christine; Henrotin, Yves ULg; Karsdal, Morten et al

in Ebiomedicine (in press)

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailNutrigenomics, Inflammaging, and Osteoarthritis: A Review
Mobasheri, Ali; Barret-Jolley, Richard; Staunton, Caroline et al

in Bagchi, Debasis; Swaroop, anand; Bagchi, Manashi (Eds.) Genomics, Proteomics and Metabolomics in Nutraceuticals and Functional Foods, 2nd Edition (2015)

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailBiomarkers of (osteo)arthritis.
Mobasheri, Ali; Henrotin, Yves ULg

in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2015), 20(8), 513-8

Arthritic diseases are a major cause of disability and morbidity, and cause an enormous burden for health and social care systems globally. Osteoarthritis (OA) is the most common form of arthritis. The ... [more ▼]

Arthritic diseases are a major cause of disability and morbidity, and cause an enormous burden for health and social care systems globally. Osteoarthritis (OA) is the most common form of arthritis. The key risk factors for the development of OA are age, obesity, joint trauma or instability. Metabolic and endocrine diseases can also contribute to the pathogenesis of OA. There is accumulating evidence to suggest that OA is a whole-organ disease that is influenced by systemic mediators, inflammaging, innate immunity and the low-grade inflammation induced by metabolic syndrome. Although all joint tissues are implicated in disease progression in OA, articular cartilage has received the most attention in the context of aging, injury and disease. There is increasing emphasis on the early detection of OA as it has the capacity to target and treat the disease more effectively. Indeed it has been suggested that this is the era of "personalized prevention" for OA. However, the development of strategies for the prevention of OA require new and sensitive biomarker tools that can detect the disease in its molecular and pre-radiographic stage, before structural and functional alterations in cartilage integrity have occurred. There is also evidence to support a role for biomarkers in OA drug discovery, specifically the development of disease modifying osteoarthritis drugs. This Special Issue of Biomarkers is dedicated to recent progress in the field of OA biomarkers. The papers in this Special Issue review the current state-of-the-art and discuss the utility of OA biomarkers as diagnostic and prognostic tools. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailWhat is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis?
Henrotin, Yves ULg; Marty, Marc; Mobasheri, Ali

in Maturitas (2014), 78

Chondroitin sulfate and glucosamine sulfate exert beneficial effects on the metabolism of in vitro models of cells derived from synovial joints: chondrocytes, synoviocytes and cells from subchondral bone ... [more ▼]

Chondroitin sulfate and glucosamine sulfate exert beneficial effects on the metabolism of in vitro models of cells derived from synovial joints: chondrocytes, synoviocytes and cells from subchondral bone, all of which are involved in osteoarthritis (OA). They increase type II collagen and proteoglycan synthesis in human articular chondrocytes and are able to reduce the production of some pro-inflammatory mediators and proteases, to reduce the cellular death process, and improve the anabolic/catabolic balance of the extracellular cartilage matrix (ECM). Clinical trials have reported a beneficial effect of chondroitin sulfate and glucosamine sulfate on pain and function. The structure-modifying effects of these compounds have been reported and analyzed in recent meta-analyses. The results for knee OA demonstrate a small but significant reduction in the rate of joint space narrowing. Chondroitin sulfate and glucosamine sulphate are recommended by several guidelines from international societies for the management of knee and hip OA, while others do not recommend these products or recommend only under condition. This comprehensive review clarifies the role of these compounds in the therapeutic arsenal for patients with knee OA [less ▲]

Detailed reference viewed: 60 (4 ULg)
Full Text
Peer Reviewed
See detailNonPharmacological modalities, nutraceuticals and dietary supplements as therapies
Henrotin, Yves ULg; Marty, Marc; Mobasheri, Ali

in Addressing Unmet Needs in Osteoarthritis (2013)

This chapter discusses and critically appraises the nonpharmacological approaches that are currently available

Detailed reference viewed: 17 (0 ULg)
Full Text
Peer Reviewed
See detailSoluble Biomarkers in Osteoarthritis – Current Status and Future Prospects?
Henrotin, Yves ULg; Mobasheri, Ali

in European Musculoskeletal Review (2012), 7(4), 217-220

There is an acute need for reliable soluble biomarkers that can facilitate earlier diagnosis of osteoarthritis (OA), inform the prognosis and monitor and predict the responses of patients to therapeutic ... [more ▼]

There is an acute need for reliable soluble biomarkers that can facilitate earlier diagnosis of osteoarthritis (OA), inform the prognosis and monitor and predict the responses of patients to therapeutic interventions. The number of biomarkers that have been validated and qualified is relatively small. This article summarises the current state of play in the field of OA soluble biomarkers. It discusses the barriers that prevent biomarkers from achieving their full potential and provides some perspectives for basic researchers and clinicians. [less ▲]

Detailed reference viewed: 130 (7 ULg)
Full Text
Peer Reviewed
See detailScientific Evidence and Rationale for the Development of Curcumin and Resveratrol as Nutraceutricals for Joint Health
Mobasheri, Ali; Henrotin, Yves ULg; Biesalski, Hans-Konrad et al

in International Journal of Molecular Sciences (2012), 13

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailIs there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?
Henrotin, Yves ULg; Mobasheri, Ali; Marty, Marc

in Arthritis Research & Therapy (2012), 14(1), 201

ABSTRACT: Glucosamine in its acetylated form is a natural constituent of some glycosaminoglycans (for example, hyaluronic acid and keratan sulfate) in the proteoglycans found in articular cartilage ... [more ▼]

ABSTRACT: Glucosamine in its acetylated form is a natural constituent of some glycosaminoglycans (for example, hyaluronic acid and keratan sulfate) in the proteoglycans found in articular cartilage, intervertebral disc and synovial fluid. Glucosamine can be extracted and stabilized by chemical modification and used as a drug or a nutraceutical. It has been approved for the treatment of osteoarthritis (OA) in Europe to promote cartilage and joint health and is sold over the counter as a dietary supplement in the United States. Various formulations of glucosamine have been tested, including glucosamine sulfate and glucosamine hydrochloride. In vitro and in vivo studies have uncovered glucosamine's mechanisms of action on articular tissues (cartilage, synovial membrane and subchondral bone) and justified its efficacy by demonstrating structure-modifying and anti-inflammatory effects at high concentrations. However, results from clinical trials have raised many concerns. Pharmacokinetic studies have shown that glucosamine is easily absorbed, but the current treatment doses (for example, 1,500 mg/day) barely reach the required therapeutic concentration in plasma and tissue. The symptomatic effect size of glucosamine varies greatly depending on the formulation used and the quality of clinical trials. Importantly, the effect size reduces when evidence is accumulated chronologically and evidence for the structure-modifying effects of glucosamine are sparse. Hence, glucosamine was at first recommended by EULAR and OARSI for the management of knee pain and structure improvement in OA patients, but not in the most recent NICE guidelines. Consequently, the published recommendations for the management of OA require revision. Glucosamine is generally safe and although there are concerns about potential allergic and salt-related side effects of some formulations, no major adverse events have been reported so far. This paper examines all the in vitro and in vivo evidence for the mechanism of action of glucosamine as well as reviews the results of clinical trials. The pharmacokinetics, side effects and differences observed with different formulations of glucosamine and combination therapies are also considered. Finally, the importance of study design and criteria of evaluation are highlighted as new compounds represent new interesting options for the management of OA. [less ▲]

Detailed reference viewed: 46 (9 ULg)